Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Revolution Medicines Inc (RVMD)

Revolution Medicines Inc (RVMD)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,695,651
  • Shares Outstanding, K 193,320
  • Annual Sales, $ 0 K
  • Annual Income, $ -600,090 K
  • EBIT $ -1,037 M
  • EBITDA $ -1,070 M
  • 60-Month Beta 0.96
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 9.40

Options Overview Details

View History
  • Implied Volatility 55.26% (-2.33%)
  • Historical Volatility 30.98%
  • IV Percentile 76%
  • IV Rank 41.49%
  • IV High 80.37% on 04/08/25
  • IV Low 37.46% on 09/18/25
  • Expected Move (DTE 21) 7.82 (9.63%)
  • Put/Call Vol Ratio 0.53
  • Today's Volume 261
  • Volume Avg (30-Day) 920
  • Put/Call OI Ratio 0.16
  • Today's Open Interest 39,685
  • Open Int (30-Day) 46,352
  • Expected Range 73.37 to 89.01

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 22 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.60
  • Number of Estimates 11
  • High Estimate -1.45
  • Low Estimate -1.69
  • Prior Year -1.12
  • Growth Rate Est. (year over year) -42.86%

Price Performance

See More
Period Period Low Period High Performance
1-Month
73.00 +11.22%
on 12/16/25
81.97 -0.95%
on 12/24/25
+7.53 (+10.22%)
since 11/24/25
3-Month
42.18 +92.48%
on 09/25/25
81.97 -0.95%
on 12/24/25
+37.65 (+86.47%)
since 09/24/25
52-Week
29.17 +178.33%
on 04/07/25
81.97 -0.95%
on 12/24/25
+36.80 (+82.90%)
since 12/24/24

Most Recent Stories

More News
Revolution Medicines Announces First Patient Randomized in the RASolute 304 Clinical Trial of Daraxonrasib in Resectable Pancreatic Ductal Adenocarcinoma Following Adjuvant Chemotherapy

REDWOOD CITY, Calif., Dec. 18, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted cancers, today announced...

RVMD : 81.19 (+1.15%)
This Oncology Stock Just Hit New All-Time Highs

Revolution Medicines (RVMD) is trading at fresh all-time highs. RVMD exhibits strong technical momentum with a 100% technical “Buy” opinion from Barchart. Shares are up nearly 60% over the past year....

RVMD : 81.19 (+1.15%)
Revolution Medicines Reports Third Quarter 2025 Financial Results and Update on Corporate Progress

Company is winding down global enrollment for the RASolute 302 clinical trial studying daraxonrasib in patients with previously treated PDAC and remains on track for data readout in 2026 Company has initiated...

RVMD : 81.19 (+1.15%)
Revolution Medicines to Participate in November 2025 Investor Conferences

REDWOOD CITY, Calif., Nov. 04, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 81.19 (+1.15%)
Revolution Medicines to Report Financial Results for Third Quarter 2025 After Market Close on November 5, 2025

REDWOOD CITY, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 81.19 (+1.15%)
Revolution Medicines’ RAS(ON) Multi-Selective Inhibitor Daraxonrasib Granted U.S. FDA Orphan Drug Designation in Pancreatic Cancer

REDWOOD CITY, Calif., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 81.19 (+1.15%)
Revolution Medicines to Present Updated Elironrasib Safety and Efficacy Data in Patients with KRAS G12C Non-Small Cell Lung Cancer Following Treatment with a KRAS(OFF) G12C Inhibitor

REDWOOD CITY, Calif., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 81.19 (+1.15%)
Revolution Medicines Awarded Voucher for Daraxonrasib (RMC-6236) Under FDA Commissioner's National Priority Voucher Pilot Program

REDWOOD CITY, Calif., Oct. 16, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 81.19 (+1.15%)
Revolution Medicines Announces Key Leadership Additions, including Alan Sandler, M.D. as Chief Development Officer

REDWOOD CITY, Calif., Sept. 29, 2025 (GLOBE NEWSWIRE) -- Revolution Medicines, Inc. (Nasdaq: RVMD), a late-stage clinical oncology company developing targeted therapies for patients with RAS-addicted...

RVMD : 81.19 (+1.15%)
Stocks Climb to Record Highs on the Outlook for Fed Rate Cuts

The S&P 500 Index ($SPX ) (SPY ) on Thursday closed up +0.85%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed up +1.36%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed up +0.60%. September E-mini...

AMAT : 261.45 (+0.26%)
CELH : 44.94 (+0.49%)
RCAT : 9.03 (-0.66%)
DHI : 146.63 (+1.50%)
RNA : 72.18 (+0.06%)
OXM : 35.48 (+1.52%)
BLDR : 104.03 (+1.30%)
$IUXX : 25,656.15 (+0.27%)
ASML : 1,069.00 (+0.33%)
ZNH26 : 112-195 (+0.08%)
ESH26 : 6,982.25 (unch)
PHM : 119.35 (+1.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strongest short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed above 70%. The market has entered overbought territory.

See More Share

Business Summary

Revolution Medicines Inc. is a clinical-stage oncology company. It is focused on developing targeted therapies to inhibit elusive frontier targets within notorious cancer pathways. Revolution Medicines Inc. is based in CA, United States.

See More

Key Turning Points

3rd Resistance Point 84.06
2nd Resistance Point 83.02
1st Resistance Point 82.10
Last Price 81.19
1st Support Level 80.14
2nd Support Level 79.10
3rd Support Level 78.18

See More

52-Week High 81.97
Last Price 81.19
Fibonacci 61.8% 61.80
Fibonacci 50% 55.57
Fibonacci 38.2% 49.34
52-Week Low 29.17

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar